Pulmonx stock has October 27, 2026 results date

Published on 10/15/2026 at 21:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

In July 2026, Pulmonx listed Zephyr Valve availability in more than 25 countries. Pulmonx stock costs EUR 1.62 on October 15, 2026 at 9:16 p.m. CEST.

Results date and market valuation

Pulmonx scheduled its third-quarter results for October 27, 2026.
In July 2026, Pulmonx listed Zephyr Valve availability in more than 25 countries.
Pulmonx stock costs EUR 1.62 at Lang & Schwarz on October 15, 2026 at 9:16 p.m. CEST, while its Nasdaq quote was up 2.25 percent.
Pulmonx had a market capitalization of USD 78.2 million on October 15, 2026.

PULM, US7458481014, Illustration mit AI erstellt.

Pulmonx stock has an October 27, 2026 results date, giving investors the next fixed checkpoint for the medical-device company. Yahoo Finance reported on October 13, 2026 that Pulmonx will publish its third-quarter results after the close of trading and hold a conference call at 4:30 p.m. ET. Pulmonx stock was at EUR 1.62 at Lang & Schwarz on October 15, 2026 at 9:16 p.m. CEST.

Zephyr remains the central product

The company is built around minimally invasive treatments for severe emphysema and chronic obstructive pulmonary disease. In its July 2026 investor presentation, Pulmonx described the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform as its core products, with Zephyr available in more than 25 countries, according to Pulmonx.

Price position and trading activity

The Lang & Schwarz quote carried a EUR 1.60 bid and a EUR 1.63 ask at the same timestamp. On Nasdaq, Pulmonx last traded at USD 1.82 on October 15, 2026 at 9:22 p.m. CEST, compared with a USD 1.78 previous close. The Nasdaq quote showed a 52-week range of USD 1.13 to USD 2.89, placing the latest home-market price 37.02 percent below the high and 61.06 percent above the low. Trading volume was 170,288 shares against an average of 487,209 shares.

Valuation before the October report

Pulmonx had a market capitalization of USD 78.2 million on October 15, 2026. Its price-to-earnings ratio was minus 1.58, while the dividend yield was 0.00 percent. The upcoming October 27 report matters because the company reported second-quarter revenue of USD 22.8 million and a diluted loss of USD 0.24 per share for the period ended June 30, 2026.

Comparison with peers

Pulmonx (Nasdaq, USD): plus 2.25 percent, P/E minus 1.58, market capitalization USD 78.2 million
Inspire Medical Systems (Nasdaq, USD): plus 2.32 percent, P/E 15.07, market capitalization USD 2.0 billion
Intuitive Surgical (Nasdaq, USD): plus 2.12 percent, P/E 48.81, market capitalization USD 151.6 billion

What comes next

The October 27 results will provide the next dated operating update, with management scheduled to discuss the figures at 4:30 p.m. ET. The company has also listed its Zephyr Valve, Chartis system and StratX platform as the main commercial pillars of its respiratory-care business.

Stock quote and outlook date

Pulmonx stock was trading at EUR 1.62 at Lang & Schwarz on October 15, 2026 at 9:16 p.m. CEST. On Nasdaq, the stock last traded at USD 1.82 on October 15, 2026 at 9:22 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Pulmonx stock.